By: Ellen Baron, PhD and Oded Ben-Joseph, PhD, MBA
Big guns may have been fired up this week in the financing world with 6 of 12 Biotech IPOs debuting and raising more than $460M dollars.
This figure however is dwarfed by the value of Merger & Acquisitions announced or offers made within healthcare during June to date — and the month isn’t quite over yet!
These deals continue a string of M&A deals announced since the start of 2018, which is headed for record highs — both in the number of deals and the size of those transactions. Overall, healthcare M&A values surged globally during 2017, rising 27% to $332 billion, while the deal count increased 16%. That very robust activity looks to be continuing in 2018.
We strongly believe that despite the recent activity in the public markets, M&A is a far superior path to return on capital for investors — and these numbers support our views.
As a result, we here at Outcome are looking forward to a busy M&A calendar for the remainder of 2018!
Tuesday, July 23 6:00-7:30pm Cost: This event is hosted by Dr. Oded Ben-Joseph (Darwin 1988), Managing Director, Outcome Capital, LLC, and is free to attend with prior RSVP. Outcome Capital, LLC 99 High Street, Suite 2900 Boston, MA RSVP to Megan Cokely at email@example.com Cambridge in America’s Boston Regional Committee invites you to another exclusive event for […]Read More
Outcome Capital Secures Growth Capital for Whisker Labs November 26, 2019, Reston, VA Outcome Capital, an investment banking firm that serves middle market growth companies in the technology and life sciences space, is pleased to announce that Whisker Labs, Inc. (the “Company”) has secured growth capital from State Farm Ventures and Ferguson Ventures along with […]Read More